SRR8518416
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- ANGIOGENESIS+0.470
- PROTEIN_SECRETION+0.390
- PANCREAS_BETA_CELLS+0.360
- UV_RESPONSE_DN+0.290
- HYPOXIA+0.280
- COAGULATION+0.200
- NOTCH_SIGNALING+0.200
- TGF_BETA_SIGNALING+0.180
- GLYCOLYSIS+0.130
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- INTERFERON_ALPHA_RESPONSE-0.520
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- E2F_TARGETS-0.370
- G2M_CHECKPOINT-0.350
- TNFA_SIGNALING_VIA_NFKB-0.350
- INFLAMMATORY_RESPONSE-0.330
- UV_RESPONSE_UP-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518264 | — | D | 0.857 |
| 2 | TCGA-CQ-7072-01A-21R-A30B-07 | — | — | 0.850 |
| 3 | TCGA-18-3409-01A-01R-0980-07 | — | cohortSQ1 | 0.830 |
| 4 | ERR2208936 | — | — | 0.825 |
| 5 | TCGA-BH-A0EI-01A-11R-A115-07 | — | B | 0.823 |
| 6 | C3L-02834 | — | cohortA1 | 0.808 |
| 7 | C3N-02145 | — | cohortA1 | 0.802 |
| 8 | b4f1e5a5-061a-498b-aadc-bd568f0e4f87 | — | — | 0.801 |
| 9 | 5af21474-88f9-4885-82d2-9c84b2ded99a | — | — | 0.800 |
| 10 | fe036511-fe82-467c-9c6e-59bfb8b0a329 | — | — | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.470 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |